Dihydroartemisinin Suppresses LOXL2-Mediated Glycerophospholipid Metabolic Reprogramming to Induce Cuproptosis in...

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, second only to lung cancer. Dihydroartemisinin (DHA), a derivative of traditional Chinese medicine, has demonstrated anticancer properties; however, its role in modulating cuproptosis remains unclear. Lysyl oxidase-like 2 (LOXL2), a copper-dependent amine oxidase, has been implicated in cuproptosis regulation, though its mechanistic involvement requires further elucidation. Using bioinformatics analysis, we analyzed the expression of LOXL2 in CRC and its relevance to genes critical for cuproptosis. After confirming LOXL2 expression in CRC cells, we moved on to transfect these cells with si-NC and si-LOXL2 to ascertain the role of LOXL2 in cuproptosis. Subsequently, we resorted to bioinformatics to pinpoint the signaling pathways that LOXL2 influences in CRC. Through untargeted metabolomics sequencing, we detected differential metabolites and enriched pathways in cells treated with si-NC and si-LOXL2, and then validated these findings at the cellular level. Molecular docking was performed to dissect the interaction between DHA and LOXL2. A suite of assays, including Oil Red O staining, Nile Red staining, CCK8 cell viability assays, western blot, flow cytometry, and immunofluorescence, was conducted to explore the potential regulatory effects of DHA on cuproptosis in CRC cells. With the aid of bioinformatics, we observed that LOXL2 levels are elevated in CRC and are negatively correlated with the expression of cuproptosis-regulating genes FDX1. Experimental validation in CRC cells confirmed that high LOXL2 expression impeded cuproptosis. Untargeted metabolomics data pinpointed the crucial role of LOXL2 in the glycerophospholipid metabolic pathway, and further cellular experiments substantiated that LOXL2-induced metabolic reprogramming of glycerophospholipids curbs cuproptosis in CRC cells. Ultimately, we elucidated the mechanism by which DHA induced cuproptosis in CRC cells, highlighting its inhibitory effect on LOXL2-mediated metabolic reprogramming of glycerophospholipids, thus suppressing tumor growth. DHA inhibits LOXL2, integral for glycerophospholipid metabolism in CRC, triggering cuproptosis and curbing tumor growth.